Clenbuterol Use in Young Healthy Adults

Regulatory Status and Guideline Absence

• The American College of Physicians, American Gastroenterological Association, and Mexican Clinical Practice Guidelines do not include clenbuterol as a recommended pharmacotherapy option for weight loss, due to its significant cardiovascular toxicity and lack of proven fat loss efficacy 1, 2, 3, 4, 5
• The American Gastroenterological Association recommends evidence-based pharmacotherapy for obesity, including FDA-approved medications such as GLP-1 agonists, naltrexone-bupropion, phentermine-topiramate, and orlistat, but not clenbuterol 3, 4

Evidence-Based Alternatives for Fat Loss

Lifestyle Interventions

• Multicomponent intensive behavioral programs with goal setting, self-monitoring, dietary change, and stress management produce 3-8% weight loss at 12-24 months, as recommended by the American Medical Association 4
• Nutritional intervention with calorie restriction and moderate-intensity physical activity is a first-line approach for weight loss, as supported by the American Heart Association 4

FDA-Approved Pharmacotherapy

• Semaglutide 2.4 mg or liraglutide 3.0 mg (GLP-1 agonists) produce superior weight loss compared to other agents, as recommended by the American Association of Clinical Endocrinologists 3, 4, 6
• Phentermine-topiramate ER produces 9.8-10.9% weight loss at 56 weeks, as supported by the American College of Cardiology 3
• Naltrexone-bupropion ER produces 6.1% weight loss and is particularly useful for patients with food cravings or concomitant depression, as recommended by the American Psychiatric Association 3, 6, 7
• Orlistat produces 2.89 kg weight loss at 12 months and is appropriate for patients with hypercholesterolemia, as supported by the American College of Gastroenterology 3, 5